Ulrich Rosentreter

This inventor holds 49 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Adenosine Receptor Modulators. Top assignees: Bayer Aktiengesellschaft, Bayer Healthcare Aktiengesellschaft, Bayer Schering Pharma Ag. Active years: 1984-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ulrich Rosentreter. Retrieved from https://idiyas.com/inventor/ulrich-rosentreter

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 49 (Patent Applications = 2)

% Patents Active = 59.2

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 5

Average Co-Inventor Count = 7.0

ph-index = 11

Forward Citations = 419(Granted Patents)

Location History:

D 51368 Leverkusen, DE (2009)
Binnen, DE (2010 - 2011)
Wuppertal, DE (1984 - 2014)

Company Filing History:

33 out of 12,268

Bayer Aktiengesellschaft

patents

5 out of 77

Bayer Healthcare Aktiengesellschaft

patents

4 out of 192

Bayer Schering Pharma Ag

patents

4. 2 out of 53

Aicuris Gmbh + Co. Kg.

patents

5. 2 out of 721

Bayer Intellectual Property Gmbh

patents

6. 1 out of 387

Bayer Pharma Aktiengesellschaft

8. 1 out of 834,570

Other

patents

Years Active: 1984-2026

Loading Chart...

Areas of Expertise:

Adenosine Receptor

Dihydropyridine Derivatives

Antiviral Compounds

Phenylaminothiazoles

Cycloalkano Indoles

Thrombosis Treatment

Inflammatory Agents

Selective Ligands

Therapeutic Agents

Neutrophil Elastase Inhibitors

Aryl Alkenoic Acids

Dihydropyrimidinones

49 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12673927 - SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION (2026-07-07),

2. 8691850 - Substituted phenylaminothiazoles and use thereof (2014-04-08),

3. 8242281 - Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands (2012-08-14),

4. 8173665 - I-pheny 1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use (2012-05-08),

5. 7919489 - Heterocyclyamide-substituted imidazoles (2011-04-05),

6. 7855219 - Substituted 2-oxy-3,5-dicyano-4aryl-6-aminopyridines and use thereof (2010-12-21),

7. 7825255 - Adenosine receptor selective modulators (2010-11-02),

8. 7767704 - Antiviral 4-aminocarbonylamino-substituted imidazole compounds (2010-08-03),

9. 7709504 - Use of Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines in the treatment of nausea and vomiting (2010-05-04),

10. 7691854 - Dihydropyridine derivatives for use as human neutrophil elastase inhibitors (2010-04-06),

11. 7687510 - Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes (2010-03-30),

12. 7566723 - 1-phenyl1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use (2009-07-28),

13. 7504421 - Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use (2009-03-17),

14. 7230017 - Dihydropyridinone derivatives (2007-06-12),

15. 7199136 - 1,4-dihydro-1,4-diphenylpyridine derivatives (2007-04-03),

Sure, here is an article about inventor Ulrich Rosentreter:

Title: The Innovative Mind of Ulrich Rosentreter

Introduction:

Ulrich Rosentreter is a brilliant inventor based in Wuppertal, Germany, with an impressive track record in the field of patents. With a total of 48 patents to his name, he has made significant contributions to the medical and pharmaceutical industries through his groundbreaking inventions.

Latest Patents:

Ulrich Rosentreter's latest patents showcase his expertise in developing novel solutions for the treatment and prevention of diseases. One of his recent inventions includes Substituted phenylaminothiazoles, which have shown great promise in treating hypertension and other cardiovascular disorders. Additionally, his work on Substituted 2,6-diamino-3,5-dicyano-4-arylpyridines as adenosine-receptor-selective ligands highlights his commitment to advancing treatments for cardiovascular disorders and diabetes.

Career Highlights:

Ulrich Rosentreter has a rich professional background, having worked at prestigious companies such as Bayer Aktiengesellschaft and Bayer Healthcare Aktiengesellschaft. His tenure at these organizations has provided him with valuable experience and insights that have undoubtedly influenced his innovative approach to inventing.

Collaborations:

Throughout his career, Ulrich Rosentreter has collaborated with esteemed professionals in the industry, including Elisabeth Perzborn and Volker-Bernd Fiedler. These collaborations have not only enriched his work but have also resulted in groundbreaking inventions that have the potential to transform the medical landscape.

Conclusion:

In conclusion, Ulrich Rosentreter stands out as a visionary inventor whose dedication to innovation has led to the creation of numerous groundbreaking patents. His relentless pursuit of finding solutions to complex medical challenges has positioned him as a key figure in the field of inventing. With a bright future ahead, Ulrich Rosentreter continues to inspire with his inventive spirit and unwavering commitment to making a positive impact on society.

Profile summary based on public USPTO records.